AbbVie is ending development of an IL-1 asset as a monotherapy in ulcerative colitis (UC) after a phase 2 study revealed ...

Researchers analyzed data from 518 visits by 254 patients (mean age, 38 years; 56.7% women), in whom disease extent was determined as ulcerative proctitis in 162 cases, left-sided ulcerative ...

The French biotech is developing a new drug approach in a disease market that’s projected to grow to $30 billion by 2030.

Greater access to innovative treatments could be linked to a drop in patients requiring surgery for a type of inflammatory ...

Shares of Abivax (NASDAQ:ABVX) surged more than 400% in Paris trading on Wednesday after the French biotech company announced that its experimental drug obefazimod met key goals in two pivotal Phase 3 ...

Ulcerative colitis is the most common cause of proctitis, but it's not the only cause. You can get proctitis from a STD or other infection, medicine, radiation therapy, or bowel surgery.

If you have ulcerative colitis, a colonoscopy is an important tool for diagnosing and monitoring your condition. It's also the best way to screen for colon cancer, which is slightly more common in ...

Patients who took JAK inhibitors were more likely to achieve endoscopic remission than those who took ustekinumab (OR 3.40, 95% CI 1.51-7.63, P =0.003) following anti-TNF therapy failure, Abbarh ...

Ulcerative colitis can also cause systemic or extraintestinal (outside the intestine) symptoms. These include fever, malnutrition, anemia, weight loss, arthritis, and more.